CD81 costimulation skews CAR transduction toward naive T cells-Reference-Cited by-同舟云学术

CD81 costimulation skews CAR transduction toward naive T cells

Published:2022-01-28 Issue:5 Volume:119 Page:
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc. Natl. Acad. Sci. U.S.A.

Author:

Schultz Liora M.¹²^ORCID,Czerwinski Debra K.¹,Levy Ronald¹^ORCID,Levy Shoshana¹^ORCID

Affiliation:

1. Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305

2. Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA 94304

Abstract

SignificanceChimeric antigen receptors (CARs) are engineered, artificial T cell receptors that can redirect cytotoxic immune T cells to eliminate cancer. Previous reports describe the benefit of less differentiated naive T cell subtypes for the purpose of CAR therapy. Here we test CD81, a T cell costimulator that preferentially activates naive T cells, for CAR engineering. We show that CD81 costimulation of naive T cells prior to CAR transduction can lead to enhanced CAR expression in this T cell subset.

Funder

St. Baldrick''''s Foundation

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Link

https://pnas.org/doi/pdf/10.1073/pnas.1910844119

Reference45 articles.

1. Clinical manufacturing of CAR T cells: foundation of a promising therapy

2. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

3. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia